Shares of Sun Pharmaceutical Industries Ltd. 524715 inched down 0.31% to 1,803.25 Indian rupees Tuesday, on what proved to be ...

Sun Pharmaceutical Industries slipped 4.30% to 1,778.85 after the US District Court of New Jersey has decided to grant a preliminary injunction delaying the launch of Leqselvi (Baldness treatment) in ...

In the worst-case scenario, an unfavourable judgment would prevent Sun Pharma from launching Leqselvi until the patent expires, delaying its market entry.

Shares of Sun Pharmaceutical fell 2.64 per cent after the pharma major recently announced that the US District Court of ...

Pharma giant, Sun Pharmaceutical's launch of its specialty drug Leqselvi in the U.S. market is in limbo as the U.S. District Court in New Jersey has issued a preliminary injunction.

Shares of Sun Pharmaceutical Industries Ltd. 524715 inched down 0.18% to 1,849.05 Indian rupees Thursday, on what proved to be an all-around rough trading session for the stock market, with the ...

Despite this setback, Sun Pharma’s stock has rallied 43 per cent year-to-date, fueled by growth in speciality drugs, emerging ...

KR Choksey recommended accumulate rating on Sun Pharmaceutical Industries with a target price of Rs 1967 in its research report dated October 30, 2024.

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Experts predict that physicians may favour emerging biosimilar versions of Stelara over more effective originator IL-23 drugs ...

The second loser today was NTPC, which operates in the Power - Generation/Distribution sector and is classified as a large cap on the BSE.

Indian generic injectables maker Gland Pharma reported a drop in second-quarter profit on Monday, hurt by lower sales in its Europe business and temporary production issues at its French ...